Gilead Slips Before Earnings as Pharma Giant Bets Big on Cancer

The day before Gilead Sciences was set to report its first-quarter numbers, investors did what investors always do when uncertainty hovers: they sold. Gilead shares dropped 1.36 percent on Thursday, shedding $1.85 to close at $134.45, even as the broader pharmaceutical sector held steadier ground.

That dip matters less than what it reveals. Here is a company sitting on a 10.72 percent gain for the year, consistently beating earnings estimates, and spending aggressively to transform itself from an HIV drug specialist into a cancer treatment company. And yet, the market remained edgy the night before results.

What the Street was watching

Wall Street expected Gilead to report earnings per share of $1.91 for the quarter, up 5.5 percent from a year ago. Revenue estimates sat at $6.92 billion, a 3.7 percent increase year-over-year. For context, $6.92 billion in a single quarter is roughly what India’s entire pharmaceutical export sector earns in two months.

Gilead had entered the quarter with momentum. Its previous report was a “double beat,” meaning the company exceeded both earnings and revenue estimates. Over the past two years, Gilead has beaten EPS targets every single quarter and exceeded revenue forecasts 88 percent of the time. That is a record most blue-chip companies would envy.

For Indian retail investors who hold international mutual funds, or who have taken the direct stock route through platforms now available in India, a stock with that kind of consistency in the $130 range carries a particular kind of appeal. It is not a volatile growth play. It is more like a high-quality compounder that happens to be betting on where medicine is going next.

The big picture: cancer drugs and a $5 billion German bet

Gilead’s share price anxiety is not about its past. It is about whether the company can pull off the transformation it has been funding aggressively.

Last month, Gilead reached a definitive agreement to acquire Tubulis GmbH, a German biotechnology firm, for up to $5 billion. Gilead will pay $3.15 billion upfront, with another $1.85 billion tied to specific development milestones, meaning it pays the remainder only if Tubulis’s drugs clear certain clinical hurdles. The deal is expected to close before the end of June.

“This is a significant milestone in Gilead’s progress in oncology,” Daniel O’Day, Gilead’s Chief Executive Officer, said when announcing the deal.

Tubulis is a specialist in what the industry calls antibody-drug conjugates, or ADCs. The concept sounds complicated but is almost elegantly simple: attach a toxic compound directly to a molecule that seeks out cancer cells, like a guided missile rather than a carpet bomb. Traditional chemotherapy attacks everything, healthy and cancerous tissue alike. ADCs try to deliver the payload only where it is needed.

This technology is one of the hottest areas in global oncology right now. Pfizer paid $43 billion for Seagen, an ADC pioneer, in 2023. That single deal reshaped the entire sector’s valuation math. Every major pharma company is now hunting for the next ADC asset, which is why Gilead’s $5 billion move looks less extravagant when placed against that backdrop.

Tubulis brings candidates in clinical trials for lung cancer, ovarian cancer, and other solid tumors. The ovarian cancer market alone is projected to reach $5.6 billion globally by 2030, according to Bloomberg Intelligence estimates. Tubulis’s pipeline would put Gilead in direct competition with AstraZeneca and Eli Lilly in that space.

Gilead’s transformation problem

Here is the tension that makes this story genuinely interesting. Gilead built its fortune on HIV drugs, and that franchise remains dominant. Its virology division generates reliable, recurring revenue that has funded this entire shopping spree. But investors have grown skeptical about whether oncology and immunology acquisitions will ever genuinely reduce that dependence.

This is the third major acquisition Gilead has announced this year alone. In February, it agreed to buy cancer biotech Arcellx for approximately $7.8 billion. In March, it announced the purchase of Ouro Medicines, focused on autoimmune conditions, for up to $2.18 billion. Add Tubulis and the total outlay this year approaches $15 billion.

Gilead already markets Trodelvy, its own ADC approved for breast cancer treatment. Adding Tubulis brings deeper research capacity, a Munich hub, and an existing collaboration with Bristol-Myers Squibb, giving the company broader pipeline and more scientific credibility in the field.

But there is a pattern that experienced pharma investors know to watch: companies that spend heavily on acquisitions often struggle to integrate the teams and genuinely advance the underlying science. Drug development timelines are long. Clinical failures are common. The billions Gilead is committing this year will take years to either justify themselves or become a cautionary tale.

What this means beyond the stock

For Indian patients and India’s pharmaceutical sector, the rise of ADCs carries a slower but real implication. When major global pharma companies pour billions into a new class of drugs, those drugs eventually reach India, but they arrive with prices that most Indian families cannot afford, often a decade or more after approval.

India’s pharmaceutical sector, which has traditionally thrived on generics, is watching this ADC wave carefully. Several domestic companies have announced early-stage research into biologics and complex molecules. ADC manufacturing, however, requires specialized infrastructure that Indian firms are only beginning to develop.

For now, the more immediate impact lands differently. Indian investors with exposure to international mutual funds, particularly those tracking US healthcare or global pharma indices, have indirect stakes in how Gilead’s oncology bet plays out. A clean beat on results would likely push the stock higher. A miss, or cautious guidance, could drag the broader pharma basket in those funds.

What to watch next

The first-quarter results, released after market close on May 7, will give the clearest signal. Analysts will focus less on the quarter’s headline numbers and more on how management discusses integration of the three major acquisitions, whether Trodelvy’s growth trajectory is holding, and whether 2026 guidance gets revised in either direction.

The guidance Gilead already issued, non-GAAP EPS of $8.45 to $8.85 for the full year, fell slightly short of what the market had hoped. Any upward revision would likely send the stock meaningfully higher. Any further trim would feed the skeptics who believe Gilead is over-spending without a clear path to reducing its HIV dependence.

The deeper story here is not one quarter of earnings. It is whether a pharma company that built its reputation fighting one of the 20th century’s most devastating viruses can now credibly fight one of the 21st century’s most persistent killers. Cancer treatment is where the money, the science, and the unmet need all converge right now. The question is whether Gilead bought the right pieces, at the right prices, fast enough to matter.